Point72 Hong Kong Ltd Purchases New Holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Point72 Hong Kong Ltd purchased a new stake in Takeda Pharmaceutical Company Limited (NYSE:TAK) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 7,100 shares of the company’s stock, valued at approximately $94,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Farther Finance Advisors LLC increased its position in Takeda Pharmaceutical by 123.6% in the 4th quarter. Farther Finance Advisors LLC now owns 3,575 shares of the company’s stock valued at $47,000 after acquiring an additional 1,976 shares during the period. Crowley Wealth Management Inc. acquired a new position in Takeda Pharmaceutical in the 4th quarter valued at about $52,000. Cromwell Holdings LLC acquired a new position in Takeda Pharmaceutical in the 4th quarter valued at about $61,000. Venturi Wealth Management LLC increased its position in Takeda Pharmaceutical by 554.7% during the 4th quarter. Venturi Wealth Management LLC now owns 5,028 shares of the company’s stock worth $67,000 after purchasing an additional 4,260 shares during the period. Finally, Lindbrook Capital LLC increased its position in Takeda Pharmaceutical by 65.0% during the 4th quarter. Lindbrook Capital LLC now owns 5,151 shares of the company’s stock worth $68,000 after purchasing an additional 2,029 shares during the period. Institutional investors and hedge funds own 9.17% of the company’s stock.

Analyst Ratings Changes

Separately, Morgan Stanley upgraded Takeda Pharmaceutical from an “equal weight” rating to an “overweight” rating in a research report on Wednesday, April 2nd.

Takeda Pharmaceutical Stock Performance

NYSE TAK opened at $14.11 on Friday. The company has a current ratio of 1.31, a quick ratio of 0.72 and a debt-to-equity ratio of 0.63. The business’s 50 day moving average is $14.76 and its two-hundred day moving average is $14.00. Takeda Pharmaceutical Company Limited has a 12-month low of $12.58 and a 12-month high of $15.43. The stock has a market capitalization of $44.88 billion, a price-to-earnings ratio of 35.26, a PEG ratio of 0.24 and a beta of 0.26.

Takeda Pharmaceutical (NYSE:TAK) last released its earnings results on Thursday, May 8th. The company reported $0.16 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.24 by ($0.08). Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. The business had revenue of $7.34 billion for the quarter, compared to analyst estimates of $8.02 billion. Research analysts expect that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current year.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.